View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
  2. Company News
July 4, 2019updated 12 Jul 2022 12:28pm

Teva reports positive data from fremanezumab’s migraine trial

Teva Pharmaceutical has announced positive findings from the exploratory endpoint analysis of the Phase IIIb FOCUS clinical trial that evaluated fremanezumab as a preventive therapy for migraine in adults.

Teva Pharmaceutical has announced positive findings from the exploratory endpoint analysis of the Phase IIIb FOCUS clinical trial that evaluated fremanezumab as a preventive therapy for migraine in adults.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Fremanezumab is a humanised monoclonal antibody that binds to and prevents the interaction of calcitonin gene-related peptide (CGRP) ligand with its receptor.

The FOCUS study assessed the safety, efficacy, and tolerability of quarterly and monthly fremanezumab therapy in episodic or chronic migraine patients who did not achieve adequate response to two to four classes of preventive drugs.

Teva’s drug was compared to placebo in the multi-centre, randomised, double-blind, parallel-group, placebo-controlled trial.

Data for exploratory endpoints showed a clinically meaningful decrease in the monthly average migraine days, while ≥50% response rates were sustained over three months and were significantly greater in patients treated with fremanezumab.

A monthly and quarterly regimen of the drug minimised migraine-related symptoms of nausea or vomiting and photophobia and phonophobia versus placebo.

Both dosing regimens also led to greater reductions from baseline in the disability score in patients treated with fremanezumab.

Results further showed improvements in quality of life and health status of participants in the active drug arm. Mean changes in quality of life were reported four weeks after the third dose.

Subjects on monthly fremanezumab also experienced improvements in depression status, compared to placebo. However, the improvements were at a lesser degree with quarterly dosing.

Teva’s medication demonstrated greater improvements from baseline in work productivity and activity impairment during the four weeks after the third dose.

Both dosing regimens were found to significantly minimise the use of acute headache medication.

Teva Migraine & Headache global medical lead Joshua Cohen said: “Data from the FOCUS study disclose the results of fremanezumab on a range of quality of life and disability measures, as well as demonstrating a significant reduction in the number of headache hours and days suffered by patients and on a spectrum of associated symptoms.”

In April this year, the Israeli company revealed plans to suspend the ENFORCE Phase III clinical development programme of fremanezumab in cluster headache following futility analysis.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena